Nutromics has been granted breakthrough device designation by the FDA for a wearable patch that continuously tracks vancomycin levels in patients. Vancomycin is a powerful antibiotic that requires careful dosing, and current practice relies on periodic blood draws to keep concentrations within a therapeutic range.
The patch is designed to provide real-time monitoring, potentially eliminating the need for repeated blood sampling. This could simplify treatment for patients and clinicians, while also enabling more precise adjustments to dosing based on continuous data.
Because the designation is a breakthrough status, it signals the FDA's recognition of the device's potential to offer a significant improvement over existing approaches. However, the patch still needs to clear further regulatory hurdles before it can reach clinical use.